Minocycline is also a cheaper and older drug with broad spectrum antimicrobial profile. It can offer some advantages over azithromycin which is being combined with HCQS in COVID-19 patients:
It does not carry any clinically significant effect on QT interval , so no risk of additive cardio-toxicity with HCQS .
It can also be helpful in preventing or treating the secondary infections which can occur in COVID patients.
It possesses a very good effect on cytokines , so can be a cheaper option in severe COVID patients having features suggestive of cytokine storm.
Your comments are awaited.
Following article is supporting the role of minocycline over azithromycin
Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management . https://academic.oup.com/ehjcvp/advance-article/doi/10.1093/ehjcvp/pvaa049/5831772
Yes it is a secondary injury support drug and not a cure for the disease so can Minocycline be a better choice for integration with HCQS in hospital patients with COVID-19
This is written with the similar idea
https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1782190
https://doi.org/10.1080/17512433.2020.18328890. We have written a review on the same idea.